PEMDOTLS: Preclinical evaluation of Miltefosin derivatives optimised for the treatment of Leishmaniasis and Sleep Disease. (Q2906826): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Removed claim: co-financing rate (P837): 66.0 percent, Removing co-finance rate from projects in portugal) |
||||||
| Property / co-financing rate | |||||||
| |||||||
| Property / co-financing rate: 66.0 percent / rank | |||||||
Revision as of 11:35, 14 September 2021
Project Q2906826 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PEMDOTLS: Preclinical evaluation of Miltefosin derivatives optimised for the treatment of Leishmaniasis and Sleep Disease. |
Project Q2906826 in Portugal |
Statements
204,000.0 Euro
0 references
26 July 2018
0 references
25 July 2022
0 references
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC
0 references
Q2985732 (Deleted Item)
0 references
41°8'58.02"N, 8°36'38.84"W
0 references
Porto
0 references
Identifiers
POCI-01-0145-FEDER-031013
0 references